China Makes Childbirth Change Amid Falling Birth Rate
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
China is moving to expand access to pain relief during childbirth as part of efforts to encourage mothers to have more children.
Newsweek reached out to the Chinese Foreign Ministry via email for comment outside of office hours.
Why It Matters
China has one of the world's lowest fertility rates, with an estimated 1.2 children per woman as of 2024. This marked a slight rise over 2023, but remains far below the replacement rate of 2.1.
The government has rolled out an array of pro-natal policies, from child subsidies to extending insurance coverage to in vitro fertilization, but with little effect, raising concerns that the shrinking pool of young workers, coupled with the rising share of retirees, will drag on growth in the world's second-largest economy.
A nurse takes care of a newborn baby at a hospital on May 11, 2025 in Lianyungang, Jiangsu Province of China. International Nurses Day falls on May 12 every year.
A nurse takes care of a newborn baby at a hospital on May 11, 2025 in Lianyungang, Jiangsu Province of China. International Nurses Day falls on May 12 every year.
Wang Chun/VCG via Associated Press
What To Know
By the end of this year, all tertiary hospitals—those with more than 500 beds—across China will be able to administer epidural anesthesia to pregnant women throughout the childbirth process, according to the country's health authorities, as reported by the state media outlet China Daily.
All secondary hospitals, or those with more than 100 beds, will be capable of providing this service by 2027.
These institutions will be expected to strengthen related infrastructure and protocols, including dedicated procedure rooms that meet a high standard of sterilization.
Efforts were also updated to include pain relief procedures throughout labor, encompassing early and post-labor assessments, as well as the diagnosis and treatment of possible complications.
Hospitals must continuously track hospital-acquired infections and improve information sharing between anesthesia and obstetrics departments to monitor patients' conditions better, the notice said.
Anesthesia is administered to just 30 percent of mothers during labor in China, compared to around 67 percent in the United States, the health officials said.
This hesitance is due to a shortage of anesthesiologists in some areas, unregulated costs of the procedure, and lingering misconceptions about possible side effects, according to experts cited by China Daily.
What People Are Saying
Yun Zhou, assistant professor of sociology at the University of Michigan, told Reuters: "Much of China's population decline is rooted in entrenched structural reasons.
"Without fundamental structural transformations—from enhancing the social safety net to eliminating gender discrimination – the trend of population decline cannot be reversed."
What Happens Next
New measures continue to be introduced at both the central and local government levels. For example, Hohhot, the capital of the Inner Mongolia Autonomous Region, announced in January a subsidy of 10,000 yuan ($1,393) to couples who have their first child.
However, experts are skeptical that these and other government-driven efforts are enough to reverse a demographic decline.
Commonly cited obstacles to parenthood in China include long working hours, the rising cost of urban living, and a lack of support for women in the workplace.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Maine won't require medical cannabis to be tested for contaminants -- this year
Jun. 11—Maine's medical cannabis providers have once again fought off a controversial requirement to start testing their products — at least for now. A legislative committee killed one bill and carried over another that would have instituted testing and tracking requirements that industry members have said for years would put them out of business or force price increases. While Maine's recreational cannabis market requires testing for contaminants and potency and includes potency limits, the medical market requires neither. Maine is the only state that doesn't mandate medical cannabis to be tested. LD 104, proposed by the state's Office of Cannabis Policy and sponsored by Rep. Marc Malon, D-Biddeford, would have required seed-to-sale plant tracking and standardized chemical, mold and heavy metal testing between recreational and medical cannabis. LD 1847, sponsored by Rep. Anne Graham, D-North Yarmouth, sought to do the same while also adding potency caps on edibles. The latter will be taken up again next year. "I have listened and I've read testimony and I've worked with public health advocates to make sure that the medical cannabis industry survives, thrives and (can) be regulated so that when patients buy cannabis, they know that they have a safe product and they know what the potency is," Graham said. " ... Clearly our regulations and how we look at (testing), it needs work, a lot of work." But it's also "hugely complicated," she said, and needs more time. Jennifer Belcher, president of the Maine Cannabis Union, said there's a "sense of relief now that we know that nothing is going through this year. If either bill passed as written, she said "the medical program would be done." Belcher was encouraged by how receptive the committee was to the industry's concerns, and while "it is nerve-racking that we are going to face this next session," there's also an exciting opportunity for collaboration. "(LD) 1847 gives us an opportunity to focus on the facts, the research, the science," she said. AN ONGOING FIGHT John Hudak, director of the office, has been clear that implementing a testing program is a top priority, but this session was the first time since he was appointed to the office in late 2022 that an official proposal has been before the committee. Following a 2022 law, any major substantive rule-making from the department must be approved by the Legislature. "If a business model is one in which producing clean cannabis is too costly, there's something wrong with the business model," he said previously. "We're not going to focus on profits at the expense of patients' health." Supporters of the bill have referenced a 2023 report by the Office of Cannabis Policy that found about 45% of the cannabis in Maine's medical market would fail the standards set for the recreational market. They also pointed to the influx of suspected illegal growers allegedly tied to Chinese organized crime who have been selling bulk cannabis at "rock bottom" prices to legal dispensaries. However, in a public hearing last month, dozens of medical cannabis caregivers and consumers testified in opposition to the bills and the committee received roughly 1,000 pieces of written testimony. They criticized the state's testing program, citing several recalls in the recreational program last year that have brought the science behind the tests and the state's standards into question. The recent recalls, they argue, prove the testing doesn't work and shouldn't be forced on the medical program. The fight is just the latest in a series of uphill battles for Maine's medical cannabis providers. Oversaturation, competition with recreational cannabis and high costs have caused revenue to plummet and people to leave the industry in droves. Unlike many other states, Maine's medical cannabis market has always outperformed its recreational counterpart. But the gap between the two is narrowing, and last year the medical market brought in about $280 million (down from $371 in 2021), while the recreational market brought in $217 million. The number of providers, known in the industry as caregivers, has been cleaved in half from its 2016 peak of 3,257 to 1,627 in May, according to state data. "We are literally fighting for our lives at this point," Belcher said. OTHER BILLS The committee carried over several other bills, including one that would require the director of the Office of Cannabis Policy be confirmed by the Legislature rather than appointed by the commissioner of the Department of Administrative and Financial Services, which oversees the office. Sen. Craig Hickman, D-Winthrop, who drafted the bill, said the committee needed time to investigate whether there are other directors, like the heads of the state's alcohol and gambling control agencies, that should also be subject to legislative approval. Lawmakers also carried over a proposal to allow cannabis "social clubs" or public consumption, based off recommendations in a task force report this winter. Earlier this session, the committee killed two bills that would have implemented revenue sharing across Maine's cannabis industry, meaning towns and cities that allow recreational businesses could receive a portion of the tax revenue they generate. Legislators hoped the bills would encourage more towns and cities to allow cannabis shops and help them recoup the costs of overseeing the recreational program. Copy the Story Link We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others. We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion. You can read more here about our commenting policy and terms of use. More information is also found on our FAQs. Show less
Newsweek
7 hours ago
- Newsweek
Long-Term Use of This Contraceptive Pill Linked to Increased Brain Tumor Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Using the progestogen-only contractive pill "desogestrel" for more than five years may increase the risk of developing a type of brain tumor known as an "intracranial meningioma," a new study has warned. The researchers noted that the risk is low—and is eliminated one year after desogestrel treatment is suspended—but that doctors' awareness of the possibility could eliminate the need for surgery in some cases. Meningiomas are a rare, non-cancerous form of tumor that arise from the membranes surrounding the brain. While slow-growing and benign in and of themselves, they can develop to a size that compresses other structures in the brain. They usually only require surgery when they cause symptoms such as persistent headaches or neurological issues. Woman holding combined oral contraceptive pill. Woman holding combined oral contraceptive pill. PATCHARIN SIMALHEK The study, based on data from France's national health system, compared over 8,000 women who underwent surgery for meningioma between 2020 and 2023 with more than 83,000 matched controls. Researchers found that women who had taken desogestrel continuously for more than five years had a slightly elevated risk of developing the brain tumors. Reassuringly, no increased risk was found for short-term use or for other commonly used progestogens like levonorgestrel, either alone or combined with estrogen. "This large study using French national database... shows [an] association between taking a certain progestogen (desogestrel) continuously for more than five years and meningioma risk, however, the magnitude of increase in the risk is small," said paper author Dr. Mangesh Thorat of Queen Mary University of London in a statement. Short-term use does not increase risk and the risk ceases after stopping use, he added. The authors estimate that one woman in every 67,000 using desogestrel would need surgery for meningioma and this drops to 1 in 17,000 with continuous use beyond five years. By comparison, breast cancer is about 10 times more common than meningioma. To understand progestogens, Thorat said it's crucial to note that the effects of different drug formulations can vary significantly and individual drugs can affect various organs differently. "Therefore, it is important to consider which specific drug is being used by an individual," he said. The study also showed that Microgynon and the morning-after pill—both containing levonorgestrel—were not linked to increased risk. Still, the findings have clinical relevance, especially for women over 45 or those with a prior history of using other high-risk progestogens. In such cases, the study suggests discontinuing desogestrel if a meningioma is identified, rather than jumping straight to surgery. "Stopping desogestrel may also avoid unnecessary potentially harmful treatments," said neurosurgeon Gilles Reuter of the University Hospital Liegein an accompanying editorial. Reuter emphasized that similar results have already been seen with other high-risk progestogens. While the study is observational and cannot prove cause and effect, its large sample size adds weight to the findings. However, experts say the takeaway should be caution, not alarm. For those affected by the findings, Thorat advises speaking with a healthcare provider regarding which drug is being used. "If it is associated with an increased risk of meningioma, this can be changed to a safer alternative," he said. "There is no reason to panic as the risk is very small and even in those who developed meningioma, stopping the specific drug has shown to cause regression in the size of meningioma." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about contraceptives? Let us know via health@ References Roland, N., Kolla, E., Baricault, B., Dayani, P., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2025). Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: National case-control study. BMJ, 389. Reuter, G. (2025). Progestogens and meningioma: New evidence on levonorgestrel and desogestrel. BMJ, 389.
Newsweek
7 hours ago
- Newsweek
Mushroom Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hofood99 Inc. is recalling packages of their Enoki Mushrooms due to fears the product may be contaminated with listeria. Newsweek reached out to the company via phone for additional comment on Wednesday and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that Listeria monocytogenes is an organism that could cause serious and sometimes fatal infections in frail or older people, young children and those with weakened immune systems. Listeria could also lead to stillbirths or miscarriages in pregnant women, the FDA says. What To Know According to the FDA alert, the mushrooms were distributed nationwide to stores and retailers. The recalled mushrooms are sold in 200-gram green plastic packaging with a with UPC Barcode of 6 976532 310051 seen on the back label. No illnesses or injuries have been reported related to the recalled mushrooms. The mushrooms were distributed by Hofood99 Inc., located at 21903 56th Avenue Oakland Gardens, New York 11364. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) What People Are Saying The FDA in the alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled mushrooms may return the product to the original place of purchase for a full refund or destroy it, the FDA says. People with additional questions may contact the company at (917) 756-9833 weekdays from 9 a.m. to 2 p.m.
